WallStSmart

Adagio Medical Holdings, Inc Common Stock (ADGM)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 26542966% more annual revenue ($36.36B vs $137,000). MDT leads profitability with a 13.2% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 62/100 (C+).

ADGM

Avoid

35

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 5.0Quality: 3.5
Piotroski: 2/9Altman Z: -4.19

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ADGM.

MDTUndervalued (+12.1%)

Margin of Safety

+12.1%

Fair Value

$91.70

Current Price

$80.52

$11.18 discount

UndervaluedFair: $91.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADGM2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
75.6%10/10

Revenue surging 75.6% year-over-year

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$103.20B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

ADGM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$16.55M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ADGM

The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ADGM

The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

ADGM profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.60 — expect wider price swings.

ADGM is growing revenue faster at 75.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 35/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adagio Medical Holdings, Inc Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing cardiac arrhythmia treatment through its state-of-the-art medical technologies. Utilizing its proprietary platform, the company is at the forefront of developing advanced targeted ablation techniques, addressing unmet needs in the electrophysiology sector. With a robust product pipeline and a seasoned leadership team, Adagio represents a compelling investment opportunity for institutional investors looking to capitalize on growth in the healthcare industry and contribute to improvements in cardiac patient outcomes.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?